技術分析

分析師

大中華區研究團隊
research-hk@uobkh.com

譚文漢，特許財務分析師
munhon.tham@uobkh.com
+852 2236 6799



藥明生物 (2269 HK)

最後價格：	港幣 40.50 元
支撐位：	港幣 33.10 元/港幣 29.94 元
阻力位：	港幣 44.72 元/港幣 46.74 元

技術分析:

价格行为在上探支撑转阻力区域时遭遇强劲压制并受阻回落，有效验证了上方供给壁垒的主导地位。动能指标进一步强化了这一看跌姿态：RSI 指标牢牢维持在看跌区间并持续向下走低。只要价格行为在盘中反弹中严格受制于支撑转阻力区域下方，结构性动态将支持行情继续向下推进，向更低的结构性支撑水平迈进。

平均時限：約兩週。



中國財險 (2328 HK)

最後價格：	港幣 16.93 元
支撐位：	港幣 15.47 元/港幣 14.83 元
阻力位：	港幣 17.28 元/港幣 17.64 元

技術分析:

价格行为在前期价格高点阻力区域处遭遇强劲拒绝，且未能成功构筑更高的高点。动能指标进一步强化了这一结构性疲态：尽管 RSI 指标目前仍维持在中性 50 门槛上方的看涨区间，但其上行动能正在明显衰减。只要价格行为在盘中反弹中严格受制于前期价格高点阻力天花板下方，结构性动态将支持行情展开看跌轮动，向前期低点支撑水平迈进。

平均時限：約兩週。

IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at this link or by scanning the QR code below:

The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."